Source map — Merck licenses a KRAS G12D inhibitor for $400M upfront
Every domain this feed has drawn corroborated signal from. We store facts and short excerpts and link back to originals — never republished article bodies.
| Source | Type | Trust |
|---|---|---|
| endpoints.news | news | 60% |
| Reuters | news | 60% |
| Fierce Biotech | news | 60% |
| Business Wire | news | 60% |
| BioSpace | news | 60% |
| www.pharmexec.com | news | 50% |
| www.merck.com | news | 50% |
| allsci.com | news | 50% |
| www.fiercebiotech.com | news | 50% |
| guavy.com | news | 50% |
| medcitynews.com | news | 50% |
| biobuzz.io | news | 50% |
| oncodaily.com | news | 50% |
| finance.yahoo.com | news | 50% |